205 related articles for article (PubMed ID: 33074401)
1. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.
Fontaine-Sylvestre C; Létourneau-Guillon L; Moumdjian RA; Berthelet F; Lacroix A
Pituitary; 2021 Apr; 24(2):207-215. PubMed ID: 33074401
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
Perosevic M; Tritos NA
Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
[TBL] [Abstract][Full Text] [Related]
3. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
[TBL] [Abstract][Full Text] [Related]
4. Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN.
Valassi E; Castinetti F; Ferriere A; Tsagarakis S; Feelders RA; Netea-Maier RT; Droste M; Strasburger CJ; Maiter D; Kastelan D; Chanson P; Webb SM; Demtröder F; Pirags V; Chabre O; Franz H; Santos A; Reincke M
Endocr Relat Cancer; 2022 Dec; 29(12):681-691. PubMed ID: 36197784
[TBL] [Abstract][Full Text] [Related]
5. The Treatment of Cushing's Disease.
Pivonello R; De Leo M; Cozzolino A; Colao A
Endocr Rev; 2015 Aug; 36(4):385-486. PubMed ID: 26067718
[TBL] [Abstract][Full Text] [Related]
6. New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.
Fleseriu M; Petersenn S
J Neurooncol; 2013 Aug; 114(1):1-11. PubMed ID: 23673515
[TBL] [Abstract][Full Text] [Related]
7. Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism.
Ferriere A; Salenave S; Puerto M; Young J; Tabarin A
Eur J Endocrinol; 2024 Jan; 190(1):L1-L3. PubMed ID: 38123490
[TBL] [Abstract][Full Text] [Related]
8. Osilodrostat in Cushing's disease: the management of its efficacy and the pitfalls of post-surgical results.
Antonini S; Brunetti A; Zampetti B; Boeris D; Saladino A; Cesare Cozzi R
Endocrinol Diabetes Metab Case Rep; 2022 Nov; 2022():. PubMed ID: 36515363
[TBL] [Abstract][Full Text] [Related]
9. Osilodrostat for Cushing Disease and Its Role in Pediatrics.
Groselj U; Sikonja J; Battelino T
Horm Res Paediatr; 2023; 96(6):573-580. PubMed ID: 35045421
[TBL] [Abstract][Full Text] [Related]
10. Severe Cushing's syndrome from an ectopic adrenocorticotropic hormone-secreting neuroendocrine tumour treated by osilodrostat.
Hána V; Brutvan T; Krausová A; Kršek M; Hána V
Endocrinol Diabetes Metab Case Rep; 2023 Oct; 2023(4):. PubMed ID: 37855644
[TBL] [Abstract][Full Text] [Related]
11. Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
Pivonello R; Fleseriu M; Newell-Price J; Shimatsu A; Feelders RA; Kadioglu P; Tabarin A; Brue TC; Geer EB; Piacentini A; Pedroncelli AM; Biller BMK
J Endocrinol Invest; 2024 May; ():. PubMed ID: 38696122
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of Drug Treatment in Cushing's Disease Not Cured by Pituitary Surgery.
Ghalawinji A; Drezet L; Chaffanjon P; Muller M; Sturm N; Simiand A; Lazard A; Gay E; Chabre O; Cristante J
J Clin Endocrinol Metab; 2024 Mar; 109(4):1000-1011. PubMed ID: 37962981
[TBL] [Abstract][Full Text] [Related]
13. Recurrent Cushing's Disease Caused by a TPIT-Lineage Densely Granulated Corticotroph Pituitary Neuroendocrine Tumor: A Case Report.
Wu W; Fu X; Guo W; Chen H
Neuro Endocrinol Lett; 2024 Jan; 45(1):76-80. PubMed ID: 38295430
[TBL] [Abstract][Full Text] [Related]
14. Fatal high-grade skull osteosarcoma 30 years following radiotherapy for Cushing's disease.
Wang M; Jonker B; Killen L; Bogum Y; McCormack A; Bishay RH
Endocrinol Diabetes Metab Case Rep; 2020 Jul; 2020():. PubMed ID: 32698127
[TBL] [Abstract][Full Text] [Related]
15. Cushing's Disease: Long-Term Effectiveness and Safety of Osilodrostat in a Polish Group of Patients with Persistent Hypercortisolemia in the Experience of a Single Center.
Dzialach L; Sobolewska J; Respondek W; Szamotulska K; Witek P
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137448
[TBL] [Abstract][Full Text] [Related]
16. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
Mallick S; Chakrabarti J; Eschbacher J; Moraitis AG; Greenstein AE; Churko J; Pond KW; Livolsi A; Thorne CA; Little AS; Yuen KCJ; Zavros Y
Transl Res; 2023 Jun; 256():56-72. PubMed ID: 36640905
[TBL] [Abstract][Full Text] [Related]
17. Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations.
Reincke M; Albani A; Assie G; Bancos I; Brue T; Buchfelder M; Chabre O; Ceccato F; Daniele A; Detomas M; Di Dalmazi G; Elenkova A; Findling J; Grossman AB; Gomez-Sanchez CE; Heaney AP; Honegger J; Karavitaki N; Lacroix A; Laws ER; Losa M; Murakami M; Newell-Price J; Pecori Giraldi F; Pérez-Rivas LG; Pivonello R; Rainey WE; Sbiera S; Schopohl J; Stratakis CA; Theodoropoulou M; van Rossum EFC; Valassi E; Zacharieva S; Rubinstein G; Ritzel K
Eur J Endocrinol; 2021 Mar; 184(3):P1-P16. PubMed ID: 33444221
[TBL] [Abstract][Full Text] [Related]
18. Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing's Syndrome.
Pivonello R; Simeoli C; Paola ND; Larocca A; Crescenzo EM; Colao A
touchREV Endocrinol; 2024 Apr; 20(1):43-51. PubMed ID: 38812665
[TBL] [Abstract][Full Text] [Related]
19. Response to Osilodrostat Therapy in Adrenal Cushing's Syndrome.
Stasiak M; Witek P; Adamska-Fita E; Lewiński A
Drug Healthc Patient Saf; 2024; 16():35-42. PubMed ID: 38616817
[TBL] [Abstract][Full Text] [Related]
20. Update on medical treatment for Cushing's disease.
Cuevas-Ramos D; Lim DST; Fleseriu M
Clin Diabetes Endocrinol; 2016; 2():16. PubMed ID: 28702250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
